Chest
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To compare the long-term effect of riociguat in PAH patients in FC I/II versus FC III/IV at PATENT-1 baseline. ⋯ Gisela Meyer: Consultant fee, speaker bureau, advisory committee, etc.: Gisela Meyer has received advisory board and speaker fees from Bayer, Lilly and GlaxoSmithKline. Nazzareno Galiè: Grant monies (from industry related sources): Nazzareno Galiè received grant money paid to his institution by Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Nazzareno Galiè received consulting fees, honorariums and/or support for travel to meetings from Bayer. Friedrich Grimminger: Grant monies (from industry related sources): Friedrich Grimminger has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Friedrich Grimminger has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare. Ekkehard Grünig: Consultant fee, speaker bureau, advisory committee, etc.: Ekkehard Grünig received support for travel to meetings from Bayer Pharma. Marc Humbert: Consultant fee, speaker bureau, advisory committee, etc.: Marc Humbert has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Zhi-Cheng Jing: Consultant fee, speaker bureau, advisory committee, etc.: Zhi-Cheng Jing has received consultancy fees and payment for lectures including service on speakers bureaus from Bayer. Anne M. Keogh: Grant monies (from industry related sources): Anne M. Keogh has received grant money paid to her institution from Bayer., Consultant fee, speaker bureau, advisory committee, etc.: Anne M. Keogh has received consultancy fees from Bayer. David Langleben: Grant monies (from industry related sources): David Langleben received grant money paid to his institution from Bayer Inc., Consultant fee, speaker bureau, advisory committee, etc.: David Langleben received consulting fees/honorarium, paid to his institution by Bayer Inc., Other: David Langleben received fees for participation in review activities, paid to his institution by Bayer Inc. Lewis J Rubin: Consultant fee, speaker bureau, advisory committee, etc.: Lewis J. Rubin has received consulting fees, honorarium and/or support for travel to meetings from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia., Other: Lewis J. Rubin has received fees for participation in review activities from Bayer, Pfizer, Actelion, GlaxoSmithKline, United Therapeutics, Gilead, GeNo, Aires, Regeneron and Liquidia. Arno Fritsch: Shareholder: Arno Fritsch has received stock/stock options from Bayer HealthCare., Employee: Arno Fritsch is a full-time employee of Bayer HealthCare. Neil Davie: Employee: Neil Davie is a full-time employee of Bayer HealthCare. Hossein-Ardeschir Ghofrani: Grant monies (from industry related sources): Hossein-Ardeschir Ghofrani has received grant money paid to his institution by Bayer HealthCare., Consultant fee, speaker bureau, advisory committee, etc.: Hossein-Ardeschir Ghofrani has received consulting fees, honorarium and/or support for travel to meetings from Bayer HealthCare.Riociguat is an investigational new drug currently in process for registration submission to health authorities, after successful finalisation of a RCT in patients with PAH.
-
Symptoms of Respiratory Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To illustrate the value of serial ventilatory and glottic responses to incremental exercise until voluntary exhaustion in an adolescent with exertional dyspnea and stridor before and after supraglottoplasty. ⋯ The following authors have nothing to disclose: Diana Orbelo, Shelagh Cofer, Paolo PianosiNo Product/Research Disclosure Information.
-
Infectious Diseases CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 04:15 PM - 05:15 PMINTRODUCTION: Daptomycin is a semisynthetic lipopeptide antibiotic, the first to be marketed, used to treat gram-positive bacterial infections, specifically skin and soft tissue infections or Staphylococcus aureus bacteremia and right-sided endocarditis. Although it cannot be used in the treatment of pneumonia, due to inactivation by pulmonary surfactant, in isolated cases it has been associated with life-threatening eosinophilic pneumonia. The majority of reported cases have high levels of serum eosinophilia. We report a case of daptomycin induced eosinophilic pneumonia without elevated serum eosinophilia. ⋯ In those patients whom daptomycin is used, we must be aware of potentially life threatening daptomycin induced lung disease, even in the absence of eosinophilia. Immediate recognition is vital as discontinuation of the offending agent alone can quickly resolve the lung disease.Reference #1: Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Kim PW, et al. Drug Saf. 2012 Jun 1;35Reference #2: Package insert. Cubicin (daptomycin). Lexington, MA: Cubist Pharmaceuticals. Aug 2010DISCLOSURE: The following authors have nothing to disclose: Anita Rajagopal, Edward Mintz, Lindsey ReeseNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Background: Chronic obstructive pulmonary disease (COPD) is a growing global epidemic especially in the developing world. It is increasingly being recognized that COPD is associated with various important comorbidities like cardiovascular diseases, osteoporosis, diabetes mellitus and metabolic syndrome. The mechanism linking COPD to systemic manifestations and comorbidities is not yet certain, but a potential mechanism to be systemic inflammation. Aim & objective: To determine the frequency of coexisting metabolic syndrome and to study the status of systemic inflammation in patients of COPD in ethnic Kashmiri population of India in view of high prevalence of COPD in them. ⋯ The following authors have nothing to disclose: Sonaullah ShahNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: We report a patient in whom pleuroperitoneal communication was diagnosed following the initiation of peritoneal dialysis (PD), in whom the PD could be continued after thoracoscopic partial resection of the diaphragm. ⋯ The following authors have nothing to disclose: Ryo Takahashi, Yuuichirou TakahashiNo Product/Research Disclosure Information.